Pharmaceuticals

Embedding ROCK-Inhibitor Fixed-Dose Combinations For Targeted Intraocular Pressure Control Is Playing A Role In Shaping The Intravenous Immunoglobulin Market

April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Intravenous Immunoglobulin Market Over The 2026–2030 Period?

The intravenous immunoglobulin market has experienced strong expansion in recent years. This market is set to expand from $15.57 billion in 2025 to $16.86 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.3%. Key factors driving this growth in the historical period include the rising prevalence of primary immunodeficiency diseases, advancements in immunoglobulin purification techniques, increased hospital-based IVIG administration, growing awareness about autoimmune disorders, and the expansion of IVIG production facilities.

The intravenous immunoglobulin market is anticipated to show significant expansion in the coming years, with its size projected to reach $23.44 billion by 2030, progressing at a compound annual growth rate (CAGR) of 8.6%. This expected growth throughout the forecast period stems from factors such as increasing demand for home-based IVIG therapy, the development of biosimilar IVIG products, the integration of automated infusion technologies, an expansion of applications for neurological disorders, and the growth of immunoglobulin therapies in emerging markets. Furthermore, major trends during this period are set to include personalized immunoglobulin therapy, home-based IVIG administration, the development and adoption of biosimilars, enhanced purification and safety protocols, and automated infusion systems.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Which Major Drivers Are Influencing The Expansion Of The Intravenous Immunoglobulin Market?

The growing elderly population is anticipated to propel the intravenous immunoglobulin market forward. The geriatric population specifically refers to individuals above 65 years of age. As people age, their immune systems often function less effectively, leading to a deficiency of antibodies. Therefore, they require immunoglobulins to provide them with these crucial antibodies. This scenario elevates the demand for intravenous immunoglobulins, consequently driving the intravenous immunoglobulin market forward. For instance, in January 2024, the Population Reference Bureau, a Kenya-based Nonprofit organization, reported that the population of Americans aged 65 and older is expected to expand from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Concurrently, this age group’s proportion of the overall population is also projected to climb from 17% to 23% during the same period. Consequently, the expanding geriatric population will significantly contribute to the growth of the intravenous immunoglobulin market.

How Is The Intravenous Immunoglobulin Market Categorized Across Its Segment Groups?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

What Trends Are Transforming The Intravenous Immunoglobulin Market?

Leading firms within the intravenous immunoglobin market prioritize launching novel products, like plasma-based medicines, and securing their approval from regulatory bodies, such as the US FDA, to enhance their market position. An FDA-approved innovative IVIG solution’s market entry indicates that the U.S. Food and Drug Administration has sanctioned a new intravenous immunoglobulin (IVIG) therapy for addressing particular medical conditions. For example, in June 2024, Biotest AG, a German company supplying plasma proteins and related products, declared its initial U.S. Food and Drug Administration (FDA) clearance for Yimmugo, intended for treating primary immunodeficiencies. As an intravenous immunoglobulin, Yimmugo incorporates pooled human plasma-derived immunoglobulin G (IgG), which is vital for providing immune support to patients with PIDs. This approval occurs against a backdrop of rising demand for plasma-based treatments, underscoring the necessity for potent therapies for individuals with weakened immune systems. Yimmugo expands Grifols’ current portfolio of intravenous and subcutaneous immunoglobulins, offering additional choices for patients who depend on these critical medications.

Which Firms Are Influencing Competition In The Intravenous Immunoglobulin Market?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Get The Full Intravenous Immunoglobulin Market Report:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Region Is The Largest In The Intravenous Immunoglobulin Market?

North America was the largest region in the intravenous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Intravenous Immunoglobulin Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Browse Through More Reports Similar to the Global Intravenous Immunoglobulin Market 2026, By The Business Research Company

Intravenous Immunoglobulin Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Subcutaneous Immunoglobulin Scig Market Report 2026

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795